세계의 흡수불량증후군 시장

Global Malabsorption Syndrome Market to Reach US$4.3 Billion by 2030

The global market for Malabsorption Syndrome estimated at US$3.5 Billion in the year 2024, is expected to reach US$4.3 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Lactose Intolerance Indication, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Sprue Indication segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$946.6 Million While China is Forecast to Grow at 7.1% CAGR

The Malabsorption Syndrome market in the U.S. is estimated at US$946.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$879.9 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Malabsorption Syndrome Market - Key Trends & Drivers Summarized

Why Is Malabsorption Syndrome Gaining Medical Attention in Gastrointestinal Healthcare?

Malabsorption syndrome is garnering increasing attention in the field of gastrointestinal health due to its complex presentation and significant impact on patient quality of life. This condition refers to the inadequate absorption of nutrients such as fats, proteins, carbohydrates, vitamins, and minerals in the small intestine, often resulting in malnutrition despite normal food intake. It can arise from various underlying disorders including celiac disease, Crohn’s disease, chronic pancreatitis, short bowel syndrome, and certain infections or surgeries that alter intestinal function. Symptoms such as chronic diarrhea, weight loss, bloating, fatigue, and nutrient deficiencies are frequently misattributed to more common gastrointestinal ailments, which complicates timely diagnosis. With greater awareness and improved diagnostic tools such as endoscopy, stool analysis, and blood nutrient profiling, clinicians are now better equipped to detect malabsorption earlier and initiate targeted interventions. The syndrome also has systemic implications, contributing to conditions like osteoporosis, anemia, and neurological dysfunction due to long-term deficiencies in calcium, iron, and B vitamins. As more healthcare providers recognize the multifactorial nature of this condition, a multidisciplinary approach involving gastroenterologists, dietitians, and endocrinologists is becoming standard. This broader recognition is helping to improve outcomes for patients who previously might have gone undiagnosed or untreated. In both developed and developing regions, the prevalence of underlying diseases that contribute to malabsorption is increasing, prompting a more robust clinical focus on early identification and management of this often-overlooked syndrome.

How Are Advances in Diagnosis and Treatment Improving Patient Outcomes?

Innovations in diagnostic methods and therapeutic strategies are significantly improving how malabsorption syndrome is identified and treated. The development of more sensitive biomarkers and non-invasive tests is allowing physicians to detect nutrient deficiencies and digestive enzyme activity with greater precision. Advanced imaging technologies such as capsule endoscopy and magnetic resonance enterography have improved the ability to visualize the small intestine and detect structural or functional abnormalities without extensive surgical intervention. Molecular testing for genetic markers associated with conditions like celiac disease is further streamlining differential diagnosis, particularly in cases with overlapping symptoms. On the treatment front, personalized nutrition plans that address specific deficiencies in iron, folate, vitamin D, and fat-soluble vitamins are playing a central role in recovery. Enzyme replacement therapies and probiotics are being used to restore digestive function and microbial balance, especially in cases stemming from pancreatic insufficiency or small intestinal bacterial overgrowth. In patients with severe or irreversible intestinal damage, interventions such as parenteral nutrition or intestinal transplantation are being employed to ensure long-term survival and nutritional adequacy. Pharmaceutical research is also advancing, with new drug formulations aimed at reducing inflammation, modulating immune response, or enhancing nutrient absorption being tested in clinical trials. These advancements are not only improving the quality of life for patients but also reducing hospital readmissions, enhancing adherence to dietary protocols, and fostering better long-term disease management. The integration of these technologies and treatments is transforming malabsorption syndrome from a difficult-to-manage condition into a more controllable and diagnosable aspect of gastrointestinal medicine.

What Epidemiological and Lifestyle Trends Are Contributing to the Rising Incidence of Malabsorption?

A combination of epidemiological and lifestyle factors is contributing to the rising incidence and diagnosis of malabsorption syndrome across global populations. One major factor is the growing prevalence of autoimmune conditions such as celiac disease and inflammatory bowel disease, both of which significantly impair nutrient absorption and are being diagnosed more frequently due to improved screening and awareness. Changes in diet, including increased consumption of processed foods low in natural enzymes and fiber, are believed to compromise digestive health and contribute to imbalances in gut flora that can precipitate or exacerbate malabsorption. Infections such as giardiasis and tropical sprue remain endemic in many low-income regions, leading to high rates of acquired malabsorption, especially in children and immunocompromised individuals. Surgical procedures like bariatric surgery and bowel resections, which are increasing in frequency, often result in a reduced absorptive surface area and create long-term challenges in maintaining adequate nutrition. Aging populations are also more prone to conditions like chronic pancreatitis and atrophic gastritis, both of which can impair digestion and absorption. In many parts of the world, socio-economic barriers to accessing fresh, nutrient-rich foods and healthcare services further compound the risks. Additionally, the use of certain medications such as antibiotics, antacids, and chemotherapy agents can disrupt gut integrity or microbial balance, indirectly triggering malabsorption issues. The convergence of these factors underscores the importance of proactive healthcare strategies that focus not only on treating symptoms but also on identifying and mitigating the root causes of malabsorption in diverse patient populations.

What Factors Are Driving Growth in the Global Malabsorption Syndrome Market?

The growth in the global malabsorption syndrome market is driven by several interrelated factors tied to rising disease prevalence, improved diagnostic capabilities, evolving treatment methodologies, and heightened public and professional awareness. Increasing rates of gastrointestinal and autoimmune disorders that frequently lead to malabsorption are expanding the pool of patients in need of long-term care and nutritional management. Advances in laboratory diagnostics and imaging have made it easier for clinicians to pinpoint the presence and causes of malabsorption, thus driving earlier and more accurate intervention. Pharmaceutical and nutraceutical companies are investing in the development of targeted therapies, including enzyme supplements, gut microbiota modulators, and specialized enteral nutrition products tailored to patients with absorption impairments. The expansion of healthcare access and reimbursement for chronic gastrointestinal care is encouraging more people to seek treatment, especially in emerging markets where previously undiagnosed cases are now entering the formal healthcare system. Telemedicine and digital health platforms are enabling broader education, follow-up, and management of malabsorption patients, helping to reduce complications and improve compliance with treatment regimens. Growing partnerships between hospitals, research institutions, and food technology firms are fostering innovation in medical nutrition products, which are essential for long-term patient support. Furthermore, educational campaigns aimed at healthcare professionals and the general public are improving recognition of malabsorption symptoms and the importance of early management. These combined factors are contributing to steady growth in the malabsorption syndrome market and reinforcing its place as a priority focus area within the broader landscape of gastrointestinal health.

SCOPE OF STUDY:

The report analyzes the Malabsorption Syndrome market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Lactose Intolerance Indication, Sprue Indication, Cystic Fibrosis Indication)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Abbott Laboratories
• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Chiesi Farmaceutici S.p.A.
• Digestive Care, Inc.
• Eli Lilly and Company
• Allergan plc
• Horizon Therapeutics plc
• Johnson & Johnson (Janssen)
• Mylan / Viatris
• Nordmark Arzneimittel GmbH & Co.
• Nestl? (Zenpep)
• Novo Nordisk A/S
• Pfizer Inc.
• Protalix BioTherapeutics Inc.
• Reddy's Laboratories
• Sanofi (Genzyme)
• Shire (Takeda)
• Ultragenyx Pharmaceutical Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Malabsorption Syndrome - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Gastrointestinal and Autoimmune Disorders Throws the Spotlight on Malabsorption Syndrome as a Growing Clinical Concern
  • Increased Awareness Among Clinicians and Patients Propels Earlier Diagnosis and Targeted Therapeutic Intervention
  • Here's the Story: Expanding Use of Genetic and Serological Testing Strengthens the Business Case for Precision Diagnosis of Malabsorption Subtypes
  • Growth in Celiac Disease, Crohn's Disease, and Pancreatic Insufficiency Drives Demand for Disease-Specific Treatment Protocols
  • Here's How Advancements in Nutritional Genomics and Microbiome Research Are Informing Personalized Dietary Management
  • Expansion of Diagnostic Imaging and Endoscopy Improves Detection of Structural and Functional Intestinal Abnormalities
  • Rising Focus on Pediatric and Geriatric Populations Spurs Demand for Tailored Malabsorption Management Strategies
  • Here's How Functional Foods and Medical Nutrition Products Are Supporting Long-Term Symptom Control and Nutrient Repletion
  • Innovation in Enzyme Replacement Therapies and Immunomodulators Fuels Development in Targeted Pharmaceutical Approaches
  • Growth in At-Home Testing and Digital Health Platforms Enhances Monitoring and Patient Engagement for Chronic Cases
  • Here's How Malabsorption Is Increasingly Recognized as a Comorbidity in Metabolic, Oncological, and Infectious Diseases
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Malabsorption Syndrome Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Malabsorption Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Malabsorption Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Malabsorption Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Lactose Intolerance Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Lactose Intolerance Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Lactose Intolerance Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Sprue Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Sprue Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Sprue Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Cystic Fibrosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Cystic Fibrosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Cystic Fibrosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 15: USA Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: USA 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 17: Canada Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 18: Canada Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: Canada 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• JAPAN
  • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 20: Japan Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 21: Japan Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: Japan 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• CHINA
  • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 23: China Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 24: China Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: China 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• EUROPE
  • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Malabsorption Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Malabsorption Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Malabsorption Syndrome by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: Europe 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• FRANCE
  • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 32: France Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: France Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: France 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• GERMANY
  • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 35: Germany Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Germany Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: Germany 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 38: Italy Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Italy Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: Italy 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 41: UK Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: UK Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: UK 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 44: Spain Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Spain Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Spain 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 47: Russia Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Russia Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Russia 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Rest of Europe Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Rest of Europe 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Malabsorption Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: Asia-Pacific Historic Review for Malabsorption Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Asia-Pacific 16-Year Perspective for Malabsorption Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Asia-Pacific Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Asia-Pacific 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 59: Australia Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Australia Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Australia 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• INDIA
  • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 62: India Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: India Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: India 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 65: South Korea Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: South Korea Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: South Korea 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Rest of Asia-Pacific Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 71: Latin America Recent Past, Current & Future Analysis for Malabsorption Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: Latin America Historic Review for Malabsorption Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Latin America 16-Year Perspective for Malabsorption Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 74: Latin America Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Latin America Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Latin America 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 77: Argentina Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Argentina Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Argentina 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 80: Brazil Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Brazil Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Brazil 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 83: Mexico Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Mexico Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Mexico 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of Latin America Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Rest of Latin America 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 89: Middle East Recent Past, Current & Future Analysis for Malabsorption Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 90: Middle East Historic Review for Malabsorption Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Middle East 16-Year Perspective for Malabsorption Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 92: Middle East Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Middle East Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Middle East 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 95: Iran Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Iran Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Iran 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 98: Israel Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Israel Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Israel 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Saudi Arabia Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Saudi Arabia 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 104: UAE Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UAE Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: UAE 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Rest of Middle East Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Rest of Middle East 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
• AFRICA
  • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 110: Africa Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Africa Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Africa 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030

IV. COMPETITION